Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Dexmedetomidine HCl (Precedex), the hydrochloride salt of Dexmedetomidine which is the dexter isomer of medetomidine, is a highly selective and potent alpha-2 adrenoceptor agonist with sedative effects. It reduces anesthetic requirements for patients by providing significant sedation. Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation.
Targets |
α2-adrenergic receptor ( IC50 = 1.08 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
Medetomidine (10-100 μg/kg; i.v. at 5-min intervals) causes a dose-dependent dilation of the pupils in rats given pentobarbitone[1].
|
|
Animal Protocol |
Female Sprague-Dawley rats (270-350 g)
1, 5, 10, 50, 100 mg/kg I.v. at 5-min intervals |
|
References |
Molecular Formula |
C13H17CLN2
|
|
---|---|---|
Molecular Weight |
236.74
|
|
Exact Mass |
236.11
|
|
Elemental Analysis |
C, 65.95; H, 7.24; Cl, 14.97; N, 11.83
|
|
CAS # |
145108-58-3
|
|
Appearance |
Solid powder
|
|
SMILES |
CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl
|
|
InChi Key |
VPNGEIHDPSLNMU-MERQFXBCSA-N
|
|
InChi Code |
InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1
|
|
Chemical Name |
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.2240 mL | 21.1202 mL | 42.2404 mL | |
5 mM | 0.8448 mL | 4.2240 mL | 8.4481 mL | |
10 mM | 0.4224 mL | 2.1120 mL | 4.2240 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04635098 | Active Recruiting |
Drug: dexmedetomidine Drug: saline |
Chronic Insomnia | Ruijin Hospital | May 14, 2021 | Not Applicable |
NCT02952222 | Active Recruiting |
Drug: Dexmedetomidine Drug: Propofol (Group P) |
Anesthesia | Keira Mason | May 11, 2018 | Phase 4 |
NCT03522688 | Active Recruiting |
Drug: Dexmedetomidine Drug: Normal saline |
Acute Kidney Injury Liver Diseases |
Asan Medical Center | July 11, 2017 | Phase 4 |
NCT03933306 | Active Recruiting |
Drug: Dexmedetomidine Drug: Placebo |
Blood Pressure Dexmedetomidine High-risk Patients |
Peking University First Hospital | May 20, 2019 | Phase 4 |
NCT05671081 | Active Recruiting |
Drug: Dexmedetomidine Drug: Magnesium sulfate Drug: Narcotic Analgesics |
Anesthesia , Analgesia | Ain Shams University | January 5, 2023 | Phase 3 |